Daily tadalafil 20 mg taken for three months did not improve cognition in patients with cerebral small vessel disease (CSVD), and the trial testing it did not meet its primary endpoint, according to two reports from the randomised, placebo-controlled, double-blind phase 2 ETLAS-2 trial (NCT05173896). The main report, published in Stroke on July 28, 2025, enrolled 76 participants (20 women, mean age 68.0 plus or minus 8.9 years) in the Capital Region of Denmark, with the first participant included on June 14, 2022 and the last visit on September 23, 2024. All had CSVD and a previous stroke or transient ischaemic attack. Seventy-one started study medication; 26 of 38 on tadalafil reached at least 90 percent compliance, against 31 of 33 on placebo (odds ratio 0.13, 95 percent confidence interval 0.03 to 0.69), so the pre-specified feasibility criterion was not met.

The imaging results were exploratory and modest. Mean white matter hyperintensity volume at baseline was 19.2 plus or minus 18.2 mL in the tadalafil group and 13.6 plus or minus 13.3 mL on placebo; the intention-to-treat analysis found no effect on log transformed volume (minus 0.045, 95 percent confidence interval minus 0.11 to 0.02, P=0.154, adjusted P=0.50). Six participants on tadalafil dropped one step on the enlarged perivascular space scale in basal ganglia and centrum semiovale, against none on placebo (P=0.018), but that difference did not survive adjustment for multiple comparisons (adjusted P=0.11). No serious drug-related adverse events were reported, the commonest side effects being gastrointestinal symptoms, headache and muscle pain.

The pre-registered cognitive sub-study, published in Cerebral Circulation: Cognition and Behavior on November 11, 2025, analysed 60 participants per protocol (28 tadalafil, 32 placebo) tested at baseline and after three months with the Symbol Digit Modalities Test, digit span forward and tests from the computerised CANTAB battery. It found no difference between groups in processing speed, attention, memory or executive function, or in any secondary outcome. One isolated result went the other way: mean simple reaction time was slower on tadalafil by 28.8 plus or minus 13.8 ms (p=0.04), which the authors themselves describe as possibly spurious. Their stated conclusion is that longer treatment duration with a PDE5 inhibitor is warranted in future trials.

The rationale for testing tadalafil, a phosphodiesterase 5 inhibitor, came partly from an earlier pilot in Brain Communications (February 2020) in which a single 20 mg dose raised blood oxygen saturation in the cortical microvasculature of 20 CSVD stroke patients by a mean 1.57 plus or minus 3.02 percent at 180 minutes, with no change on transcranial Doppler or peripheral endothelial testing. ETLAS-2 was designed as a feasibility trial and aimed for 100 patients; it recruited 76, and the imaging and cognitive analyses were exploratory sub-studies rather than powered efficacy endpoints. The authors call for larger and longer studies, and raise the possibility of lower tadalafil doses given the adherence problem. The trial was investigator-initiated and supported by a Novo Nordisk Foundation grant to the senior author.